Trial reportBMC anesthesiology2025
Nebulization with differently sized 2% lidocaine atomized particles in awake tracheal intubation by video laryngoscopy: a proof-of-concept randomized trial.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06420947 (Application of Electrically Driven Atomized Surface Anesthesia to Awake Endotracheal Intubation in Patients With Predictably Difficult Airway.), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Application of Electrically Driven Atomized Surface Anesthesia to Awake Endotracheal Intubation in Patients With Predictably Difficult Airway.
Who cites it
2 citing papers in PubMed.
- Ultrasound-guided modified superior laryngeal nerve block for awake tracheal intubation in patients with difficult airways.BMC anesthesiology · 2026Article
- Lidocaine Delivery Systems for Preventing Postoperative Sore Throat: From Direct Spray to Soft Mist.Local and regional anesthesia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOptimization of the individual topicalization technique during awake tracheal intubation (ATI) is critical, but how to accomplish this is still unknown. We hypothesized that there would be a difference between nebulization with different sizes of 2% lidocaine atomized particles in ATI by video laryngoscopy.
methodsA total of 230 patients scheduled for ATI were recruited from September 2024 through January 2025. Forty-six participants were excluded, and 184 participants were randomly assigned to 4 treatment groups according to the size of the atomized particles of 2% lidocaine: A3 (3-4 μm), A6 (6-7 μm), A9 (9-10 μm), or A11 (11-12 μm).
resultsThere were statistically significant differences among the four groups. Post hoc analysis using Dunnett test showed that, compared with the A3 group, the A9 group had greater feelings of comfort (cough score: P = 0.005; reaction score: P = 0.024; discomfort score: P = 0.003). the A9 group had lower heart rates at endotracheal tube insertion(P = 0.015), at inflation of the tracheal tube cuff (P = 0.001) and 1 min after endotracheal tube insertion(P = 0.009); The A9 group had fewer applications of the airway spray and fewer times the patient vomited (P<0.001), but exhibited a longer nebulization time (P<0.0001).
conclusionIn conclusion, we demonstrated that there were differences between nebulization with different sizes of 2% lidocaine atomized particles in ATI. In addition, 2% lidocaine administered via a nebulizer with 9-10-µm atomized particles performed better during ATI. Therefore, we recommend a nebulizer and the 9-10-µm particle-size range for patients who need ATI.
trial registrationClinicaltrials.gov, NCT06420947. Date of Registration: May 12th, 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.